Patent Term Application for HYRNUO (sevabertinib), Patent No. 10,428,063 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

FDA-2026-E-4532

Patent Term Application for HYRNUO (sevabertinib), Patent No. 10,428,063

Documents

Comments

Key Dates

Comment Period OpensApr 27, 2026

Type	Title	Posted	Comments	Status
Supporting Material	Patent Term Extension Application from Bayer HealthCare LLC - Exhibits A-C US Patent 10428063	Apr 27, 2026	--	--

CDER

Bayer HealthCare LLC

Patent Term Application for HYRNUO sevabertinib

Patent No 10428063

OPEN